Epitope mapping of PfCP-2.9, an asexual blood-stage vaccine candidate of Plasmodium falciparum.
BACKGROUND
Apical membrane antigen 1 (AMA-1) and merozoite surface protein 1 (MSP1) of Plasmodium falciparum are two leading blood-stage malaria vaccine candidates. A P. falciparum chimeric protein 2.9 (PfCP-2.9) has been constructed as a vaccine candidate, by fusing AMA-1 domain III (AMA-1 (III)) with a C-terminal 19 kDa fragment of MSP1 (MSP1-19) via a 28-mer peptide hinge. PfCP-2.9 was highly immunogenic in animal studies, and antibodies elicited by the PfCP-2.9 highly inhibited parasite growth in vitro. This study focused on locating the distribution of epitopes on PfCP-2.9.


METHODS
A panel of anti-PfCP-2.9 monoclonal antibodies (mAbs) were produced and their properties were examined by Western blot as well as in vitro growth inhibition assay (GIA). In addition, a series of PfCP-2.9 mutants containing single amino acid substitution were produced in Pichia pastoris. Interaction of the mAbs with the PfCP-2.9 mutants was measured by both Western blot and enzyme-linked immunosorbent assay (ELISA).


RESULTS
Twelve mAbs recognizing PfCP-2.9 chimeric protein were produced. Of them, eight mAbs recognized conformational epitopes and six mAbs showed various levels of inhibitory activities on parasite growth in vitro. In addition, seventeen PfCP-2.9 mutants with single amino acid substitution were produced in Pichia pastoris for interaction with mAbs. Reduced binding of an inhibitory mAb (mAb7G), was observed in three mutants including M62 (Phe491-->Ala), M82 (Glu511-->Gln) and M84 (Arg513-->Lys), suggesting that these amino acid substitutions are critical to the epitope corresponding to mAb7G. The binding of two non-inhibitory mAbs (mAbG11.12 and mAbW9.10) was also reduced in the mutants of either M62 or M82. The substitution of Leu31 to Arg resulted in completely abolishing the binding of mAb1E1 (a blocking antibody) to M176 mutant, suggesting that the Leu residue at this position plays a crucial role in the formation of the epitope. In addition, the Asn15 residue may also play an important role in the global folding of PfCP-2.9, as its substitution by Arg lead to reduced binding of most mAbs and abolishing the binding of mAb6G and mAbP5-W12.


CONCLUSIONS
This study provided valuable information on epitopes of PfCP-2.9 vaccine candidate through generation of a panel of mAbs and a series of PfCP-2.9 mutants. The information may prove to be useful for designing more effective malaria vaccines against blood-stage parasites.
Li
Changling
C
Department of Pathogenic Biology, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China.
Wang
Rui
R
Wu
Yuan
Y
Zhang
Dongmei
D
He
Zhicheng
Z
Pan
Weiqing
W
D000595:Amino Acid Sequence; D019943:Amino Acid Substitution / Q000235:genetics; D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood / Q000235:genetics / Q000276:immunology*; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping / Q000379:methods*; D000939:Epitopes; D004912:Erythrocytes / Q000276:immunology; D017780:Malaria Vaccines / Q000097:blood / Q000235:genetics / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D010843:Pichia / Q000235:genetics / Q000276:immunology; D010963:Plasmodium falciparum / Q000235:genetics / Q000254:growth & development / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
D000911:Antibodies, Monoclonal; D000939:Epitopes; D017780:Malaria Vaccines; C535092:PfCP2.9 vaccine; D014614:Vaccines, Synthetic
J Biol Chem. 2001 Aug 17;276(33):31311-20
11399764
Infect Immun. 2002 Sep;70(9):5328-31
12183594
Nature. 1975 Aug 7;256(5517):495-7
1172191
Mol Microbiol. 2000 Nov;38(4):706-18
11115107
J Mol Biol. 2007 Mar 9;366(5):1523-37
17229439
Curr Opin Microbiol. 2005 Aug;8(4):422-7
16019257
Infect Immun. 2005 Apr;73(4):2116-22
15784553
Mol Biochem Parasitol. 2005 Nov;144(1):55-67
16154214
PLoS One. 2008 Apr 09;3(4):e1952
18398475
Vaccine. 2007 Mar 1;25(11):2112-9
17241708
PLoS Pathog. 2005 Nov;1(3):241-51
16322767
Biochemistry. 2005 Jan 18;44(2):518-23
15641776
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12295-300
14526103
J Mol Biol. 2003 May 16;328(5):1091-103
12729744
J Biol Chem. 2003 Jun 27;278(26):23890-8
12686561
Nat Med. 2000 Jan;6(1):91-5
10613831
Vaccine. 2008 Dec 9;26(52):6864-73
18930094
J Immunol. 2008 Dec 15;181(12):8776-83
19050299
Mol Biochem Parasitol. 2004 Sep;137(1):143-9
15279960
J Mol Biol. 1999 May 28;289(1):113-22
10339410
Gene. 1989 Apr 15;77(1):51-9
2744487
Malar J. 2010 Mar 18;9:76
20236549
J Immunol. 2004 May 15;172(10):6167-74
15128804
J Mol Biol. 2002 Sep 27;322(4):741-53
12270711
J Mol Biol. 2001 Apr 13;307(5):1381-94
11292349
Mol Biochem Parasitol. 2004 Nov;138(1):29-36
15500913
J Mol Biol. 1991 Feb 20;217(4):721-9
2005621